June 5, 2007 — Strong industry interest in SilvaGard, a breakthrough antimicrobial nanotechnology, has resulted in significant growth for AcryMed, the company that developed and now licenses the technology.
Built on years of research in developing silver antimicrobial wound treatments, SilvaGard addresses a still un-met clinical need, preventing the spread of deadly medical device-related infections.
By harnessing the advantages of nanotechnology with the broad-spectrum infection-fighting ability of Ionic silver, SilvaGard provides a safe and effective solution to render medical devices impervious to infection causing biofilms.
SilvaGard prevents the spread of device-related infections by depositing antimicrobial silver nanoparticles onto the surfaces of medical devices and thus providing a protective barrier. Studies have shown that SilvaGard is not only safe for use, but also highly effective against a wide spectrum of infection-causing bacteria including MRSA and other antibiotic-resistant "superbugs."
To accommodate the increased demand for its patented technologies, AcryMed has recently doubled the size of its laboratory facilities and hired new scientific and technical staff.
"The spread of hospital acquired infections is a significant problem that unnecessarily effect millions of U.S. patients each year and adds more than 28 billion dollars to our nation's healthcare costs," said Jack McMaken, president of AcryMed. "Since a large portion of harmful bacteria is harbored on medical devices such as indwelling catheters and implants, manufacturers are extremely interested in finding ways to curtail the role their products play in spreading infections. SilvaGard represents the first significant breakthrough in this area in quite some time."
For more information visit: www.acrymed.com